Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Chandana Javvaji (NPI 1821437716)

Field	Value
Entity Type	Individual
Organization	Chandana Javvaji
Address	230 Nebraska St
City	Sioux City
State	IA
ZIP	51101
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 24, 2013

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

This profile is effectively single‑payer Medicare: lifetime Medicare revenue is $1.6M while there is no Medicaid billing on file (none). The provider’s NPI has been enumerated since 2013-06-24 (~13 years ago), indicating an established presence in the Medicare market.

Revenue is highly concentrated in a small set of high-cost oncology drugs: the precomputed top three Medicare codes account for 83.2% of this provider’s total Medicare revenue, driven primarily by J9271 ($885.8K, 56.7%) and J9299 ($322K, 20.6%), with J0897 contributing $92.9K (5.9%). This concentration means most Medicare dollars flow through a few injectable treatments rather than office visits or ancillary services.

The code mix identifies a medical oncology infusion practice focused on checkpoint inhibitors and supportive oncology care. Large revenues from J9271 (pembrolizumab) and J9299 (nivolumab), combined with chemotherapy administration codes such as 96413 ($35.1K, 2.2%) and add‑on codes 96411/96417, plus supportive agents like J2506 (pegfilgrastim, $18.7K, 1.2%) and J0897 (denosumab), point to routine infusion services with drug administration as the primary service line.

Competitive standing on the top drugs is mixed: J9271 ranks #365 of 1841 providers nationally (80th percentile; typical, unremarkable volume for this code), indicating above‑median activity but not dominance, while J9299 ranks #271 of 505 providers nationally (46th percentile; typical, unremarkable volume for this code), reflecting only modest participation in that agent. J0897 sits at #2733 of 10057 (73th percentile; typical, unremarkable volume for this code), showing a relatively common but not leading role in denosumab administration.

Office evaluation and management revenue is present but small relative to drug revenue: 99214 produced $44.9K (2.9%) and 99215 produced $23.3K (1.5%) of Medicare revenue, suggesting that patient visits and physician time are secondary revenue drivers compared with infused oncology therapeutics. This pattern is consistent with an infusion‑center model where high-cost drugs dominate reimbursement.

Laboratory and venipuncture activity is elevated versus national peers, supporting an infusion/oncology workflow that requires frequent labs and blood draws: 80053 (CMP) shows 1.2K claims and $12.1K (0.8%) revenue and ranks #1150 of 26416 providers nationally (96th percentile), 85025 (CBC) shows 1.3K claims and $10.7K (0.7%) revenue and ranks #1668 of 32833 (95th percentile), and 36415 shows 1K claims and $8.1K (0.5%) revenue with a 97th percentile rank. These high percentiles indicate more intensive lab/collection volume than typical for the average national provider.

Participation in biosimilars and less common therapeutics appears limited but present: Q5115 (rituximab‑abbs, truxima) produced $38.8K (2.5%) and ranks #77 of 79 providers nationally (3th percentile; typical, unremarkable volume for this code), implying the provider bills this biosimilar but is low in the national rank order for that specific code. Similarly, J2506 (pegfilgrastim) ranks #485 of 586 providers nationally (15th percentile; typical, unremarkable volume for this code), showing modest use of growth‑factor support relative to peers.

For payer strategy and contracting considerations, the dominant exposure to high‑cost injected oncology agents (J9271 $885.8K and J9299 $322K) suggests that reimbursement and drug acquisition terms for these agents will be the primary drivers of financial performance on Medicare. Given the lack of Medicaid billing (none), any network/contracting decisions or utilization management initiatives should be evaluated against an essentially Medicare‑only billed revenue base for this clinician.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

69 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,600	$40	$885.8K
J9299	Injection, nivolumab, 1 mg	14,000	$20	$322K
J0897	Injection, denosumab, 1 mg	5,160	$20	$92.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	520	$90	$44.9K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	1,140	$30	$38.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	370	$90	$35.1K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	180	$130	$23.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	370	$60	$21.6K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	230	$80	$18.7K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	1,210	$10	$12.1K

Showing 1–10 of 69

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 69 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Chandana Javvaji — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

69 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	30	17,200	$40	$902.3K
J9299	5	10	18,700	$20	$527.6K
J0897	38	190	1,920	$20	$74.1K
Q5115	9	10	1,790	$30	$71.4K
J2506	15	20	440	$80	$38.9K
96413	20	80	210	$90	$24K
99214	458	4,690	100	$70	$14.4K
99233	355	910	60	$90	$10.5K
99232	958	1,740	80	$60	$9.3K
99213	394	4,740	100	$50	$8K

Showing 1–10 of 69

Related Providers

Other providers that share a Tax Identification Number (TIN) with Chandana Javvaji, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mary Washington Hospital Inc.	VA	General Acute Care Hospital	$0	$80.1M
Northwest Iowa Hospital Corporation	IA	General Acute Care Hospital	$0	$22.8M
Northwest Iowa Hospital Corporation	IA	Emergency Medical Services (Emergency Medicine) Physician	$0	$7.9M
Donald Wender	IA	Hematology & Oncology Physician	$2.6M	$0
Nibash Budhathoki	MO	Hematology & Oncology Physician	$2.2M	$0
Lisa Chaiken	CA	Radiation Oncology Physician	$1.6M	$0
Jay Robinow	KS	Radiation Oncology Physician	$1.2M	$0
Jason Bailey	CA	Diagnostic Radiology Physician	$848.4K	$20
Curtis Burhoop	NE	Diagnostic Radiology Physician	$687.7K	$0
Wesley Pruett	MN	Diagnostic Radiology Physician	$441.3K	$770

Nearby Providers

Other providers in the same ZIP code as Chandana Javvaji, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jackson Recovery Centers, Inc.	IA	Substance Abuse Rehabilitation Facility	$0	$28.5M
Siouxland Mental Health Services, Inc.	IA	Community/Behavioral Health Agency	$0	$25.7M
City Of Sioux City Accounting Division	IA	Ambulance	$520.5K	$19.2M
Marian Health Center-smhc	IA	General Acute Care Hospital	$0	$15.5M
Family Health Care Of Siouxland Plc	IA	Family Medicine Physician	$0	$11.1M
Family Wellness Associates, Inc.	IA	Community/Behavioral Health Agency	$0	$4M
Woodbury Emergency Group, PC	IA	Emergency Medicine Physician	$0	$3M
Building Bridges Counseling & Associates Inc	IA	Community/Behavioral Health Agency	$0	$2.5M
Mercy Medical Services	IA	Internal Medicine Physician	$0	$2M
Counseling And Support Services Inc	IA	Social Worker	$0	$1.8M

Chandana Javvaji — Billing Profile & Reimbursement Data

Sign up for Chandana Javvaji — Billing Profile & Reimbursement Data policy alerts

Chandana Javvaji — Billing Profile & Reimbursement Data

Sign up for Chandana Javvaji — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References